Recursion Pharmaceuticals annual revenue
2019
2020
2021
2022
2023
2024
2025
Recursion Pharmaceuticals Revenue Growth & History (RXRX)
Recursion Pharmaceuticals reported $74.7M in revenue for fiscal 2025, an increase of 26.92% from the previous fiscal year.
View full Recursion Pharmaceuticals company overviewRecursion Pharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $74.7M | $15.8M | +26.92% |
| 2024 | 2024-12-31 | $58.8M | $14.3M | +32.00% |
| 2023 | 2023-12-31 | $44.6M | $4.7M | +11.88% |
| 2022 | 2022-12-31 | $39.8M | $29.7M | +291.46% |
| 2021 | 2021-12-31 | $10.2M | $6.2M | +156.89% |
| 2020 | 2020-12-31 | $4.0M | $1.6M | +70.85% |
| 2019 | 2019-12-31 | $2.3M | — | — |
Recursion Pharmaceuticals quarterly revenue
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.7M | −$11.6M | −60.10% |
| Q1 2026 | 2026-03-31 | $6.5M | −$8.3M | −56.11% |
| Q4 2025 | 2025-12-31 | $35.5M | $31.0M | +681.74% |
| Q3 2025 | 2025-09-30 | $5.2M | −$20.9M | −80.16% |
| Q2 2025 | 2025-06-30 | $19.2M | $4.8M | +33.34% |
| Q1 2025 | 2025-03-31 | $14.7M | $951,000 | +6.89% |
| Q4 2024 | 2024-12-31 | $4.5M | −$6.3M | −58.26% |
| Q3 2024 | 2024-09-30 | $26.1M | $15.5M | +147.62% |
| Q2 2024 | 2024-06-30 | $14.4M | $3.4M | +30.86% |
| Q1 2024 | 2024-03-31 | $13.8M | $1.7M | +13.68% |
| Q4 2023 | 2023-12-31 | $10.9M | −$2.8M | −20.36% |
| Q3 2023 | 2023-09-30 | $10.5M | −$2.6M | −19.96% |
| Q2 2023 | 2023-06-30 | $11.0M | $3.3M | +43.56% |
| Q1 2023 | 2023-03-31 | $12.1M | $6.8M | +127.53% |
| Q4 2022 | 2022-12-31 | $13.7M | $11.1M | +439.91% |
| Q3 2022 | 2022-09-30 | $13.2M | $10.6M | +419.34% |
| Q2 2022 | 2022-06-30 | $7.7M | $5.1M | +201.06% |
| Q1 2022 | 2022-03-31 | $5.3M | $2.8M | +108.16% |
| Q4 2021 | 2021-12-31 | $2.5M | −$158,000 | −5.87% |
| Q3 2021 | 2021-09-30 | $2.5M | $1.5M | +147.22% |
| Q2 2021 | 2021-06-30 | $2.5M | $2.4M | +1270.43% |
| Q1 2021 | 2021-03-31 | $2.6M | $2.5M | +4170.00% |
| Q4 2020 | 2020-12-31 | $2.7M | — | — |
| Q3 2020 | 2020-09-30 | $1.0M | — | — |
| Q2 2020 | 2020-06-30 | $186,000 | — | — |
| Q1 2020 | 2020-03-31 | $60,000 | — | — |
Recursion Pharmaceuticals revenue growth trends
Over the last five reported fiscal years, revenue grew from $4.0M to $74.7M, a compound annual growth rate of 79.91%. Recursion Pharmaceuticals's latest reported quarter, Q2 2026, generated $7.7M in revenue, a decrease of 60.10% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Recursion Pharmaceuticals source filings ↗